Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease
Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease
复制标题
DOI：
10.1053/j.ajkd.2005.10.022
复制
发表时间：
2006-02-01
影响因子：
13.2
通讯作者：
Bremner, WJ
中科院分区：
文献类型：
--
作者：
Brockenbrough, AT;Dittrich, MO;Bremner, WJ
背景 性腺功能减退症和贫血是透析患者常见的合并症。睾酮替代疗法可以改善贫血、肌肉减少症和性欲低下等临床参数。此外，通过增加血红蛋白水平，睾酮替代可以减少重组人促红细胞生成素（rHuEPO）的剂量，从而降低成本。方法：这项 IV 期、单中心、安慰剂对照、双盲研究评估了透皮睾酮对血清睾酮水平、维持血红蛋白水平所需的 rHuEPO 剂量、骨矿物质含量、去脂体重和脂肪含量、胆固醇水平、性功能和情绪的影响。 40 名接受 rHuEPO 治疗的性腺功能减退男性血液透析患者被随机分配至 100 mg 局部 1% 睾酮凝胶（Testim；Auxilium Pharmaceuticals，Norristown，PA）或安慰剂组，每日使用，持续 6 个月。结果：40 名男性平均年龄为 56 岁，基线血清睾酮水平低于 300 ng/dL（
Background Hypogonadism and anemia are common comorbid conditions in dialysis patients. Testosterone replacement may improve such clinical parameters as anemia, sarcopenia, and low libido. Additionally, by increasing hemoglobin levels, testosterone replacement may allow for a dose reduction in recombinant human erythropoietin (rHuEPO), thereby reducing cost. Methods: This phase IV, single-center, placebo-controlled, double-blind study assessed the effect of transdermal testosterone on serum testosterone levels, rHuEPO dose required to maintain hemoglobin level, bone mineral content, lean body mass and fat content, cholesterol level, sexual function, and mood. Forty hypogonadal male hemodialysis patients who were administered rHuEPO were randomly assigned to 100 mg of topical 1% testosterone gel (Testim; Auxilium Pharmaceuticals, Norristown, PA) or placebo, applied daily for 6 months. Results: Forty men with a mean age of 56 years and baseline serum testosterone level less than 300 ng/dL (